SERUM AND CSF DRUG LEVELS AND D2 OCCUPANCY FOR PALIPERIDONE AND RISPERIDONE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 多巴胺D2受体家族的拮抗作用是抗精神病作用的关键，中枢D2受体的占有率与抗精神病作用的阈值和锥体外系副作用(EPS)的阈值有关。然而，以前的研究没有对同一组患者进行D2结合潜力(Bmax)的基线测量，而是依赖于来自单独的、混合的健康受试者和药物新药患者组的年龄校正估计。我们已经完成了猴的剂量、血清水平和脑脊液水平之间的关系的研究，并正在分析结果。我们已经完成了对不同剂量药物的中心D2占有率的研究，使用了连续的PET扫描。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Antagonism of the D2 family of dopamine receptors is critical for antipsychotic action and occupancy of central D2 receptors has been related a threshold for antipsychotic effect, as well as a threshold for extrapyramidal side effects (EPS). However, previous studies did not perform baseline measurements of D2 binding potential (Bmax) in the same cohort of patients, but rather relied on an age corrected estimate from a separate, mixed group of healthy subjects and drug na¿ve patients. We have completed our study of the relationship between dose, serum level and cerebrospinal fluid level in monkeys and are analyzing the results. We have completed our study of the central D2 occupancy of drug at different doses using serial PET scans.